IDEXX Laboratories (IDXX) news
Recent news
Barclays cuts target price to $710 from $800 for Idexx Laboratories, Inc.
Barclays has revised its price target for IDEXX Laboratories, Inc. (IDXX) to $710 from $800, reflecting a more cautious outlook on the stock's near-term performance. The adjustment was made following a reassessment of the company's growth trajectory and market conditions, though the firm has not…
AInvest Wire · Aug 11, 2026IDEXX Laboratories shares up 9.5% after Q2 revenue beats estimates
IDEXX Laboratories, Inc. (IDXX) reported second-quarter 2026 results on August 4, with shares rising 9.5% in pre-market trading following the earnings release. The company posted quarterly earnings per share (EPS) of $3.95, exceeding the Zacks Consensus Estimate by 8.8% and reflecting a…
AInvest Wire · Aug 4, 2026IDEXX Laboratories outlook FY reported operating margin 32.3% - 32.5%
AInvest Wire · Aug 4, 2026IDEXX Laboratories Inc: UBS cuts target price to $620 from $640
UBS has revised its price target for IDEXX Laboratories Inc (NASDAQ: IDXX), lowering it to $620 from a previous $640. The adjustment reflects the firm’s updated assessment of the company’s near-term outlook and market dynamics. IDEXX, a leading provider of diagnostic and information solutions for…
AInvest Wire · Jul 27, 2026IDEXX Laboratories Q2 2024 Adj. EPS $3.02 Beats $2.88 Estimate, Sales $1.004B Miss $1.007B Estimate
AInvest Wire · Aug 6, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.